To determine whether hematopoietic stem cell transplantation (HSCT) can improve patient prognosis, we conducted survival analyses of METTL3‐positive and WTAP‐positive AML patients who underwent HSCT and those who did not. The gene discussed is WTAP; the disease is acute myeloid leukemia.